Disease · MONDO_0013189
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 12 of 12
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Memantine vs Placebo: deaths from any cause | 0 of 55 | 0 of 45 | 100 | NCT04792645 | Trial comparisons |
| Memantine vs Placebo: serious adverse events | 0 of 55 | 0 of 45 | 100 | NCT04792645 | Trial comparisons |
| Memantine vs Placebo: Clinical Global Impressions-Improvement Scale (CGI-I) | 26 of 43 | 3 of 36 | 79 | NCT04792645 | Trial comparisons |
| Naltrexone vs Placebo: serious adverse events | 0 of 25 | 0 of 26 | 51 | NCT00775229 | Trial comparisons |
| N-Acetyl Cysteine vs Placebo: serious adverse events | 0 of 25 | 0 of 25 | 50 | NCT00354770 | Trial comparisons |
| Dronabinol vs Placebo: deaths from any cause | 0 of 25 | 0 of 25 | 50 | NCT03530800 | Trial comparisons |
| Dronabinol vs Placebo: serious adverse events | 0 of 25 | 0 of 25 | 50 | NCT03530800 | Trial comparisons |
| N-acetylcysteine (NAC) vs Placebo: serious adverse events | 0 of 20 | 0 of 19 | 39 | NCT00993265 | Trial comparisons |
| Milk Thistle vs Placebo: deaths from any cause | 0 of 18 | 0 of 21 | 39 | NCT02473913 | Trial comparisons |
| Milk Thistle vs Placebo: serious adverse events | 0 of 18 | 0 of 21 | 39 | NCT02473913 | Trial comparisons |
| Inositol vs Placebo: deaths from any cause | 0 of 19 | 0 of 19 | 38 | NCT01875445 | Trial comparisons |
| Inositol vs Placebo: serious adverse events | 1 of 19 | 0 of 19 | 38 | NCT01875445 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0013189/comparisons